How to Trade This Emerging GARP Healthcare Name

Astrana Health (ASTH), a healthcare management company, reported Q2 revenue growth of 49% YoY and expects 25% growth in FY2026. The company has a market cap of $1.9B, trades at $38/share, and aims to reduce its leverage ratio. Analysts project EPS to triple this year and continue growing. The author suggests a covered call strategy for investing in ASTH.

Original reporting
Published Oct 25, 2026, 3:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 3:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
How to Trade This Emerging GARP Healthcare Name — source image
Decision brief

The 30-second read

$ASTHNeutralLow
01

Why it matters

Provides a specific trade structure but no new corporate event; serves as a tactical suggestion for existing shareholders or new entrants.

02

Market read

Targeted at traders seeking exposure to mid‑cap healthcare with AI-driven cost efficiencies; relevance limited to niche investors.

03

What to watch

Potential integration risks from the $700 M Prospect Health acquisition and debt leverage.

Relevance 4/10Novelty 2/10Timing: none

Background

The article is a trade recommendation column discussing Astrana Health's business model, recent acquisition, financials, and a covered‑call option play.

Company-level read

Ticker impact

$ASTHNeutralMedium confidence
Context

The article introduces Astrana Health (ASTH) as an emerging GARP healthcare trade, detailing its recent acquisition, financial metrics and a covered‑call strategy.

Expected impact

limited upside as the covered‑call trade caps gains while providing downside buffer

Evidence & confidence

The piece offers a trade idea rather than new corporate news; impact depends on execution of the option strategy rather than a catalyst.

Market effects

Highlights interest in mid‑cap healthcare GARP stocks leveraging AI and acquisitions.

US healthcare sector focus; no broader regional effect.

Limited to investors tracking niche healthcare opportunities.

Counterpoint

Without fresh growth catalysts, the stock may face valuation pressure despite the covered‑call shield.

Key entities

  • Astrana Health, Inc.

    Emerging GARP healthcare management firm.

Related articles

$ASTHHighAI 8/10

Astrana Health Earnings Call Highlights Growth and Deleveraging

Astrana Health (ASTH) reported Q3 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). The company highlighted organic growth, debt reduction, and favorable Medicare trends. Management maintained full-year guidance, expecting revenue of $3.9B-$4B and adjusted EBITDA of $261M-$274M. Challenges include Medicaid pressure and seasonality.

$ASTHMed

Astrana Health 3Q 2026: Revenue $1.02B, EPS $0.26 — 10-Q Summary

Astrana Health reported 3Q 2026 revenue of $1.02B, up 7% YoY, and net income of $13.0M, compared to $373K last year. Growth was driven by 9% increase in capitation revenue. Care Partners saw 8% revenue growth and 94% operating income rise, while Care Delivery revenue increased 5% but operating loss widened. Care Enablement revenue rose 5% with 4% higher operating income. Astrana managed 29 IPAs and 1.5M patients as of September 30, 2026.

$ASTHMed

Astrana Health Inc (ASTH) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA

Astrana Health Inc (ASTH) reported Q3 2026 earnings, highlighting record revenue and EBITDA growth. CEO Brandon Sim discussed Medicaid membership attrition, Medicare Advantage dynamics, and care enablement business momentum. The company expects mid-teens EBITDA growth despite Medicaid headwinds. A cybersecurity incident is under investigation, and a new 'premiums at risk' disclosure was introduced for ACO business transparency.

$ASTHHighAI 8/10

Astrana Health (ASTH) Q3 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). Membership grew to 1.5M, with Medicare Advantage increasing organically. The company completed acquisitions and partnerships, expanding its presence. Medical cost trends were slightly better than expected, with Texas operations performing ahead of plan. Free cash flow reached $105M, and net leverage was reduced to 2.2x.

$ASTHMed

Astrana Health Q3 Earnings Call Highlights

Astrana Health reported 1.5 million members under management, with Medicare Advantage growth offsetting Medicaid attrition. The company expects Medicaid membership to decline 10-15% in 2027, impacting adjusted EBITDA. Medical cost trends were slightly better than expected, with Medicare Advantage margins stable. Astrana plans 82% of capitation revenue from full-risk arrangements by 2026 and completed acquisitions and partnerships.